A Phase II study to evaluate the efficacy of erlotinib in advanced NSCLC patients who have wild-type EGFR and EGFR gene amplification.

Takashi Sone,Tomoyuki Araya,Yuichi Tambo,Kazuhiko Shibata,Shingo Nishikawa,Ryo Matsunuma,Toshiyuki Kita,Koji Kurokawa,Hiroki Shirasaki,Masaru Nishitsuji,Josuke Hara,S. Nomura,Hayato Koba,Tamami Sakai,Hirokazu Touge,Yoshihisa Ishiura,Shunichi Tamori,Hideharu Kimura,Taro Yoneda,Kazuo Kasahara

A Phase II study to evaluate the efficacy of erlotinib in advanced NSCLC patients who have wild-type EGFR and EGFR gene amplification.

2015

e19028 Background: Erlotinib is one of the standard therapies for previously treated patients (pts) of advanced non-small-cell lung cancer (NSCLC) without EGFR mutations. However, response rate of ...

Keywords:

Pathology
Phases of clinical research
EGFR Gene Amplification
Erlotinib
Wild type
Cancer research
Medicine
egfr mutation
Lung cancer
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations